Cargando…

MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2

BACKGROUND: Papillary thyroid carcinoma (PTC), with a rapidly increasing incidence, is the most prevalent malignant cancer of the thyroid. However, its pathogenesis is unclear and its specific clinical indicators have not yet been identified. There is increasing evidence that microRNAs (miRNAs) play...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yonglian, Zhang, Hengwei, Wang, Lidong, Liu, Chenxi, Guo, Mingyue, Tan, Hao, Liu, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447791/
https://www.ncbi.nlm.nih.gov/pubmed/34530821
http://dx.doi.org/10.1186/s12935-021-02083-8
_version_ 1784569092134404096
author Huang, Yonglian
Zhang, Hengwei
Wang, Lidong
Liu, Chenxi
Guo, Mingyue
Tan, Hao
Liu, Zhen
author_facet Huang, Yonglian
Zhang, Hengwei
Wang, Lidong
Liu, Chenxi
Guo, Mingyue
Tan, Hao
Liu, Zhen
author_sort Huang, Yonglian
collection PubMed
description BACKGROUND: Papillary thyroid carcinoma (PTC), with a rapidly increasing incidence, is the most prevalent malignant cancer of the thyroid. However, its pathogenesis is unclear and its specific clinical indicators have not yet been identified. There is increasing evidence that microRNAs (miRNAs) play important roles in tumor occurrence and progression. Specifically, miR-613 participates in the regulation of tumor development in various cancers; however, its effects and mechanisms of action in PTC are still unclear. Therefore, in this study, we investigated the expression and function of miR-613 in PTC. METHODS: qRT-PCR was used to determine miR-613 expression in 107 pairs of PTC and adjacent-normal tissues as well as in PTC cell lines and to detect TAGLN2 mRNA expression in PTC tissues and adjacent normal tissues. Western blot analysis was performed to identify TAGLN2 and epithelial–mesenchymal transition (EMT) biomarkers. The effects of miR-613 on PTC progression were evaluated by performing MTS, wound-healing, and Transwell assays in vitro. Luciferase reporter assays were also performed to validate the target of miR-613. RESULTS: In PTC, miR-613 was significantly downregulated and its low expression level was associated with cervical lymph node metastasis. However, its overexpression significantly suppressed PTC cell proliferation, migration, and invasion and inhibited EMT. TAGLN2 was identified as a target of miR-613, which also significantly inhibited the expression of TAGLN2. Further, the restoration of TAGLN2 expression attenuated the inhibitory effects of miR-613 on PTC cell proliferation and metastasis. CONCLUSION: Our findings demonstrated that miR-613 can suppress the progression of PTC cells by targeting TAGLN2, indicating that miR-613 plays the role of a tumor suppressor in PTC. Overall, these results suggest that the upregulation of miR-613 is a promising therapeutic strategy for PTC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02083-8.
format Online
Article
Text
id pubmed-8447791
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84477912021-09-20 MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2 Huang, Yonglian Zhang, Hengwei Wang, Lidong Liu, Chenxi Guo, Mingyue Tan, Hao Liu, Zhen Cancer Cell Int Primary Research BACKGROUND: Papillary thyroid carcinoma (PTC), with a rapidly increasing incidence, is the most prevalent malignant cancer of the thyroid. However, its pathogenesis is unclear and its specific clinical indicators have not yet been identified. There is increasing evidence that microRNAs (miRNAs) play important roles in tumor occurrence and progression. Specifically, miR-613 participates in the regulation of tumor development in various cancers; however, its effects and mechanisms of action in PTC are still unclear. Therefore, in this study, we investigated the expression and function of miR-613 in PTC. METHODS: qRT-PCR was used to determine miR-613 expression in 107 pairs of PTC and adjacent-normal tissues as well as in PTC cell lines and to detect TAGLN2 mRNA expression in PTC tissues and adjacent normal tissues. Western blot analysis was performed to identify TAGLN2 and epithelial–mesenchymal transition (EMT) biomarkers. The effects of miR-613 on PTC progression were evaluated by performing MTS, wound-healing, and Transwell assays in vitro. Luciferase reporter assays were also performed to validate the target of miR-613. RESULTS: In PTC, miR-613 was significantly downregulated and its low expression level was associated with cervical lymph node metastasis. However, its overexpression significantly suppressed PTC cell proliferation, migration, and invasion and inhibited EMT. TAGLN2 was identified as a target of miR-613, which also significantly inhibited the expression of TAGLN2. Further, the restoration of TAGLN2 expression attenuated the inhibitory effects of miR-613 on PTC cell proliferation and metastasis. CONCLUSION: Our findings demonstrated that miR-613 can suppress the progression of PTC cells by targeting TAGLN2, indicating that miR-613 plays the role of a tumor suppressor in PTC. Overall, these results suggest that the upregulation of miR-613 is a promising therapeutic strategy for PTC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02083-8. BioMed Central 2021-09-16 /pmc/articles/PMC8447791/ /pubmed/34530821 http://dx.doi.org/10.1186/s12935-021-02083-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Huang, Yonglian
Zhang, Hengwei
Wang, Lidong
Liu, Chenxi
Guo, Mingyue
Tan, Hao
Liu, Zhen
MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2
title MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2
title_full MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2
title_fullStr MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2
title_full_unstemmed MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2
title_short MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2
title_sort mir-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting tagln2
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447791/
https://www.ncbi.nlm.nih.gov/pubmed/34530821
http://dx.doi.org/10.1186/s12935-021-02083-8
work_keys_str_mv AT huangyonglian mir613inhibitstheproliferationmigrationandinvasionofpapillarythyroidcarcinomacellsbydirectlytargetingtagln2
AT zhanghengwei mir613inhibitstheproliferationmigrationandinvasionofpapillarythyroidcarcinomacellsbydirectlytargetingtagln2
AT wanglidong mir613inhibitstheproliferationmigrationandinvasionofpapillarythyroidcarcinomacellsbydirectlytargetingtagln2
AT liuchenxi mir613inhibitstheproliferationmigrationandinvasionofpapillarythyroidcarcinomacellsbydirectlytargetingtagln2
AT guomingyue mir613inhibitstheproliferationmigrationandinvasionofpapillarythyroidcarcinomacellsbydirectlytargetingtagln2
AT tanhao mir613inhibitstheproliferationmigrationandinvasionofpapillarythyroidcarcinomacellsbydirectlytargetingtagln2
AT liuzhen mir613inhibitstheproliferationmigrationandinvasionofpapillarythyroidcarcinomacellsbydirectlytargetingtagln2